NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 420
(Total Views: 98)
Posted On: 01/04/2024 3:32:24 PM
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of Rybelsus(R)-Branded GLP-1 Drug Semaglutide
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced positive final results from its recently completed human Pilot Study #1 evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide available commercially in the branded product Rybelsus(R). According to the announcement, the study was performed by a prominent university research center comparing a single 7 mg semaglutide dose of a Rybelsus tablet (“control”) to a matching dose from Rybelsus that had been compound formulated in capsule form using DehydraTECH processing technology enhancements (“DehydraTECH GLP-1”). In general, the DehydraTECH processing enabled improvements in delivery of semaglutide to the bloodstream, and the improvements in controlling blood sugar were more pronounced in the final combined results than they were in the first half of the study as reported in press releases issued Nov. 27 and 28, 2023.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced positive final results from its recently completed human Pilot Study #1 evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide available commercially in the branded product Rybelsus(R). According to the announcement, the study was performed by a prominent university research center comparing a single 7 mg semaglutide dose of a Rybelsus tablet (“control”) to a matching dose from Rybelsus that had been compound formulated in capsule form using DehydraTECH processing technology enhancements (“DehydraTECH GLP-1”). In general, the DehydraTECH processing enabled improvements in delivery of semaglutide to the bloodstream, and the improvements in controlling blood sugar were more pronounced in the final combined results than they were in the first half of the study as reported in press releases issued Nov. 27 and 28, 2023.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼